Ironwood Pharmaceuticals Files to Begin China Phase III Trial of Linaclotide
Published: Jul 18, 2012
July 17, 2012 -- Ironwood Pharmaceuticals has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide. Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world. More details....
Stock Symbol: (NSDQ: IRWD)